J&J's Janssen Reports New Darzalex Phase 3 Study Showed Efficacy, Safety Data On Anti-CD38 Monoclonal Activity In Newly-Diagnosed Transplant Patients, Says Median Progression-Free Survival Has Not Yet been Reached